Is Halozyme Therapeutics, Inc. overvalued?

Halozyme Therapeutics, Inc. (HALO) looks fairly valued — trading about 3% below its fair value.

Fairly valued

Price

$113.90

Fair value

$117.77

Current P/E

24.7

Normal P/E

25.5

Market cap

$13.51B

Dividend yield

0.0%

Return on equity

180.6%

Sector

Healthcare

Fair value compares HALO's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.

Related stocks